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Major Histocompatibility Complex Class II molecules (MHCII) play a critical 
role in immunity. Of key importance is the presentation of antigenic peptides to CD4+ 
effector T cells of the adaptive immune system. During the assembly of MHCII 
molecules, a conserved chaperone protein known as invariant chain binds MHCII with a 
segment buried in the MHCII binding groove. Invariant chain functions to track MHCII 
into endocytic peptide loading compartments, prevents inappropriate peptide binding, and 
assists to maintain the structure of MHCII. After the complex enters the peptide loading 
compartment invariant chain is sequentially cleaved to leave only a small fragment, class 
II associated invariant chain (CLIP), bound through the peptide binding groove. CLIP 
must be removed prior to antigenic peptide loading in the peptide binding groove. The 
process of peptide exchange occurs through a series of events that are not completely 
understood. The research described herein is aimed at further elucidated the role that a 
second peptide plays in the dissociation of a prebound peptide.  
 As with most assays involving the dissociation of a species which could possibly 
rebind, the peptide dissociation from MHCII has traditionally been performed using an 
excess of unlabeled peptide which can rapidly block the binding site to prevent rebinding 
of the labeled peptide. As with most „competition‟ type assays, it was assumed that the 
unlabeled peptide did not affect the dissociation of bound, labeled peptide. Recent
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evidence has suggested that the unlabeled peptide might play a role in the dissociation of 
the labeled peptide; in fact this recent data suggests that a second peptide in solution is 
required for peptide to dissociate from MHCII.   
By using several different analytical techniques to measure the dissociation in the 
absence and presence of competitors with varying affinity for MHCII we show that each 
individual peptide has a rate of dissociation, which occurs independently of the presence 
of a second peptide in solution. These findings lead to the conclusion that dissociation 
and exchange of peptides on MHCII is a random process that is determined solely by the 
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The presentation of antigen to CD4+ T cells, in the context of major 
histocompatibility complex class II proteins (MHCII), is a key event in the generation of 
an adaptive immune response to a foreign pathogen. MHCII are highly polymorphic, 
heterodimeric, glycoproteins manufactured in the endoplasmic reticulum of specialized 
cells known as antigen presenting cells (APC). MHCII consist of noncovalently linked 
alpha and beta chains, encoded by the HLA-DR gene locus on chromosome 6 in the 
human genome (1). The alpha and beta chains are integral membrane proteins comprised 
of approximately 250 amino acids. They consist of an extracytoplasmic region divided 
into two domains, transmembrane domains of approximately 25 amino acids, and internal 
cytoplasmic regions of approximately 12 amino acids (2). A simplified representation of 
the structure of MHC II is shown in Figure 1. The membrane proximal domains are 
termed alpha 2 and beta 2, and are linked by an internal disulfide bond. The distal 
regions, alpha 1 and beta 1 are linked by an eight stranded beta pleated sheet, covered by 
two alpha helices, which results in a cleft capable of binding peptides referred to as the 
peptide binding groove (3). The ribbon diagram in Figure 2 more clearly illustrates the 
structural characteristics of MHC II.  
The presence of a peptide in the binding groove is a requirement for proper 















Figure 2. Ribbon diagram illustrating the structural organization of MHCII with a bound 
peptide. The two alpha helices composing the peptide binding groove, in pink, are seen 
surrounding the CLIP 102-113 peptide, in white. RCSB PDB ID: 10.2210/pdb3pgd/pdb. 
Gunther, S., Schlundt, S., Sticht, J., Roske, Y., Heinemann, U., Wiesmullerr, K.H., Jung, G., 
Falk, K., Rotzschke, O., Freund, C. Bidiractional binding of invariant chain peptides to an 




shift rendering it incapable of rapid, efficient peptide binding (4,5). MHCII molecules are 
manufactured in the endoplasmic reticulum as trimers, with a protein referred to as 
invariant chain (Ii) occupying the peptide-binding groove. Ii is a type II transmembrane 
glycoprotein, encoded on chromosome 5. Four isoforms, differentiated by primary amino 
acid sequence, are known to exist in humans. The dominant isoform, referred to as p33, is 
a 216 amino acid protein, with an N-terminal cytosolic tail and transmembrane region of 
approximately 30 amino acids each and a 160 amino acid C-terminal lumen domain (6,7). 
Following assembly, it is necessary for the MHCII/Ii complex to move into late 
endosomes, referred to as MHCII loading compartments (MIIC‟s).  
MIIC‟s are acidic, protease rich endosomal compartments within the cell. These 
areas are ideal for the internalization of exogenous proteins, which are rapidly degraded 
to peptides capable of being loaded onto MHCII. It is not clear the exact path by which 
MHCII-Ii complexes reach the MIIC‟s. Some reports suggest a direct method, moving 
from the trans-golgi network (TGN) into the endocytic pathway (8,9), while other studies 
have pointed to a route in which the complexes first move to the plasma membrane after 
which they are rapidly internalized (10, 11). Despite the exact route, Di- leucine like 
trafficking signals in the cytoplasmic portion of Ii are important for transfer of the 
complex into the MIIC.  
 Various types of intracellular sorting signals are known to occur on 
transmembrane proteins. Two such signals have been identified on Ii. The membrane 
distal signal is comprised of leucine and isoleucine at position 7 and 8; and a more 
proximal signal at residues 16 and 17 consisting of methionine and leucine (10). Either of 
the signals alone has been shown to be sufficient for endosomal localization of MHCII-Ii 
(12). It is possible that the lack of one or the other of these signals may lead to alternate 
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transport mechanisms into the MIIC and could explain the discrepancy reported in the 
literature.  
Following entry of the complex into the MIIC, Ii is sequentially degraded leaving 
a residual class II associated peptide (CLIP). CLIP is generally considered to encompass 
the amino acids from position 81-104 of Ii, with the core binding residues of 91-99 (13). 
CLIP remains deeply buried in the MHCII peptide groove, inaccessible to further 
degradation by proteases. The presence of CLIP in the binding groove has recently been 
shown to play a more critical role in immune activation than its previously thought action 
of maintaining the integrity of the binding site and the conformation of MHCII. MHCII-
CLIP complexes at the cell surface have been shown to be necessary for T cell activation 
as well as being required for the active maintenance of peripheral self- tolerance (14, 15). 
Despite this necessity of persistent MHCII-CLIP complexes, for antigen presentation to 
occur CLIP must be removed from a portion of MHCII to allow subsequent antigen 
binding. The kinetics of removal, however, are too slow to permit efficient peptide 
exchange in the time that MHCII is transported to the cell surface. An additional 
accessory protein, human leukocyte antigen-DM (HLA-DM), co- localizes to the 
endosomes with MHCII and accelerates peptide exchange. 
HLA-DM shares approximately 28% sequence similarity with MHCII, and is also 
encoded on the MHCII locus of chromosome 6. The sequence similarity between the two 
proteins leads to similar folding and structural organizations. A ribbon diagram of HLA-
DM illustrating the structural similarities compared to MHCII (Figure 2) is shown in 






Figure 3. A ribbon diagram illustrating the structure of HLA-DM. RCSB PDB ID: 
10.2210/pdb2bc4/pdb. Nicholson, M.J., Moradi, B., Seth, N.P., Xing, X., Cuny, G.D., 
Stein, R.L., Wucherpfennig, K.W., Small molecules that enhance the catalytic efficiency 








HLA-DM in the region which comprises the peptide binding groove of MHCII, 
preventing HLA-DM from effectively associating with peptide (16, 17). The importance 
of HLA-DM in peptide dissociation has been shown in a variety of studies, with some of 
the most compelling evidence coming from studies utilizing HLA-DM knockout mice. In 
HLA-DM negative mice, MHCII congregate at the cell surface in normal concentrations, 
but CLIP represents the majority of the bound peptide, indicating that MHCII trafficking 
and assembly in the absence of HLA-DM is normal but peptide exchange is inhibited (18, 
19).   
HLA-DM acts to stabilize empty MHCII and catalyzes peptide dissociation and 
exchange through a transient, yet unknown interaction (20). A tyrosine based signaling 
motif of HLA-DM targets its transport to MIIC compartments where it congregates with 
MHCII molecules. The signal sequence retains HLA-DM in the endosomes, preventing 
its accumulation at the cell surface (21, 22). Although a direct physical interaction and 
the general orientation between HLA-DM and MHCII, during efficient peptide exchange, 
have been noted in the literature (23, 24), the exact mechanism by which the bonds of 
MHCII are altered to catalyze peptide dissociation and loading remains a mystery.      
Peptide bonding to MHCII is accomplished via two sets of interactions; first, 
amino acid side chains of the binding peptide fit as anchors within the backbone structure 
of the binding groove. The pocket anchor interactions determine peptide binding 
specificity. The anchor residues are conventionally referred to using the prefix P with the 
corresponding number of the residue, with P1 being nearest the peptide N terminus. The 
second set of interactions holding the peptide in place, hydrogen bonds formed between 
conserved amino acids of the MHCII protein and the bound peptide, provide
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basal stability and constrain the conformation of bound peptide (25, 26). These conserved 
interactions lead to peptides binding in what has been termed nested sets, with similar 
conserved amino acids at certain positions within peptides (27).  
The conserved hydrogen bond network is a tempting target for investigators, and 
disruption of these bonds by HLA-DM has been theorized to be a key feature of the 
catalytic mechanism of peptide dissociation (28, 29). Although individual components of 
this hydrogen bond network have been singled out and studied via mutant MHCII 
proteins lacking certain amino acids in the peptide binding groove, Zhou et al. have most 
recently provided evidence that no one single residue is responsible for the catalytic 
mechanism of HLA-DM, and a series of cooperative interactions are more likely 
responsible for the enhancement of peptide dissociation (26).  
Regardless the mechanism of peptide dissociation and binding, the process has 
typically been viewed as occurring as singular events, as shown in Figure 4. Initially 
HLA-DM catalyzes CLIP removal, subsequently stabilizing the empty MHCII protein, 
followed by binding of alternate peptides (20, 30, 31). Essentially, peptides present in 
higher concentrations will be more likely to interact with MHCII and, it follows, more 
likely to bind. It is important to remember, though, that peptides have varying affinities 
for MHCII and when a high affinity peptide binds it is less likely to dissociate and be 
replaced during the time of transport of MHCII to the cell surface.  
An alternate theory to this singular dissociation and binding process is a theory 
termed „push off‟, in which a second peptide is able to bind to MHCII simultaneously 
with the pre-bound peptide, leading to more rapid dissociation (32, 33, 34). The majority 






Figure 4. MHCII pathway to antigen loading and presentation at the cell surface. (1) MHCII gene transcription due to the MHCII 
transactivator (CIITA). (2) MHCII are transferred to the endoplasmic reticulum where they assemble with invariant chain as 
nonameric complexes. (3) MHCII-Ii complexes translocate to the trans-golgi network. (4) They move into the late endosomes or 
MHCII loading compartments. Ii is degraded to CLIP and they can associate with the antigens which have been endocytosed. (5) 







the peptide groove and indeed, studies confirming that there are secondary sites on 
MHCII proteins to which peptides are able to bind have been published (33,35). One 
notable study used high concentrations of peptides and Forster Resonance Transfer 
(FRET). Kropshofer et al. noted energy transfer upon the addition of 15 M of two 
different peptides to the MHC solution simultaneously, but little energy transfer was seen 
when one peptide was added followed by the second peptide. This finding might indicate 
that when added at sufficient concentrations, two peptides interact prior to association 
with the MHCII resulting in both peptides partially binding but this scenario is not likely 
representative of an endogenous process (33).  
Recently, Ferrante et al. revisited this phenomenon and published a set of 
complex biophysical data indicating that not only are two peptides able to bind 
simultaneously, but the presence of a second peptide is a requirement of peptide 
dissociation (34). One of the confounding factors of most peptide dissoc iation studies is 
the necessity of a second, unmeasured peptide in excess in solution. The presence of this 
peptide serves the function of rapidly binding the empty site following peptide 
dissociation, preventing rebinding of the labeled peptide. The effec t of this competitor 
peptide on dissociation of the bound peptide, however, has never been fully investigated 
in MHCII peptide dissociation. Based on the findings of Ferrante et al., this second 
peptide is not simply blocking the binding site but plays an active role creating it. This 
finding was extremely controversial to the regarded mechanism of peptide dissociation 
and we set out to more completely explore the phenomena.  
Here we have designed a set of experiments to clearly and specifically investigate 
the dissociation of peptide under various conditions to clarify the „push off‟ theory. We 
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theorized that the resultant change of rate due to the presence of the competitor was due 
to the competitor being present at excess concentrations to rapidly associate with MHCII 
and block the peptide binding groove. By conducting experiments at lower concentrations 
of complex than are typically used, 50-100 nM, we were able to show the contribution of 
rebinding in the apparent change in rates seen in the absence of competitor. Additionally, 
we show that dissociation of a given peptide occurs at nearly an identical rate regardless 
of the competitor affinity for MHCII. This is directly counter to the prediction made 
based on the two peptide model. Our data clearly support the hypothesis that peptide 
exchange on MHCII molecules occurs at a given rate determined by the affinity of the 
bound peptide and the presence of secondary peptides in solution is not a requirement, 
nor does it have an effect on the rate of dissociation.
Experimental Background 
In biological systems, life is dependent on specific interactions between 
molecules. Various methods have been developed and described to measure these 
interactions in the laboratory. MHC-peptide interactions are commonly measured by 
using a labeled peptide, which can be quantitated upon separation from MHCII. Early 
methods used radioactive labels, but due to the expense, health consequences and 
regulation, these labels are used infrequently nowadays. More common is the use of a 
fluorescent tag, although biotin labels have been used as well. Separation techniques 
include chromatography, antibody separations and even simple molecular weight cutoff 
filters (36, 37). One interesting technique to detect protein binding takes advantage of the 
stability of the alpha and beta chains when certain peptides are bound. Although no 
specific label is required for this technique, it is only useful for certain MHCII peptide 
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complexes. These peptides generally have an aliphatic or aromatic residue occupying the 
P1 pocket of MHCII (38). This alpha beta chain stability allows approximation of 
dissociation rates to be measured using sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE).  
Several of these techniques are represented in this study, however the separation 
step can complicate the assay. In particular, it is time consuming, and can lead to 
erroneous results when a large number of peptides or rapidly dissociating peptides are 
being studied. For this reason, the majority of these experiments were performed using 
fluorescence polarization (FP). In recent years FP has seen increasing use in laboratory 
protein interaction measurements. FP, first described by Perrin in 1926, allows 
measurement of interactions in solution and in real time (39). Therefore the time 
consuming step is the sample preparation, and critical to this method is to rapidly add the 
reagents to prevent excess reaction from proceeding prior to initiation of measurement. 
FP is based on the fact that a fluorophore, when excited by plane-polarized light, will 
emit plane-polarized light. As illustrated in Figure 5, the degree of polarization is 
determined by the rate of rotation of the flourophore during the emission period 
(rotational relaxation time), which generally occurs in nanoseconds (ns). As shown by
 
A=3cos2 -1/5                                                        (1)
 
 
where A is the anisotropy, the orientation of the emitted light depends on the angle ( ) 
between the orientations of the absorbing and emitting fluorophore (40). When the angle 
is equal to zero, and assuming no rotation of the fluorophore during the emission period, 





Figure 5. Representation of a stationary fluorophore and a rotating fluorophore. The florophore which remains stationary during the 
period of emission emits 60% of the light parallel to the excitation light. In the case of the rotating fluorophore less than 60% of the 







light is detected in the same plane as the exciting light and 40% in a perpendicular 
direction measured by the instrument, Figure 6.  
The rate of rotation is determined by the molecular volume of the species to 
which the fluorophore is attached. In the case of our peptide dissociation experiments, a 
fluorescent label is attached to the small peptide which is then loaded on the much larger 
MHCII protein. In this state the rate of rotation is slow, leading to a higher degree of 
polarization. Over time, as the peptide dissociates the average degree of rotation increases 
and polarization subsequently decreases, Figure 7.  The calculation for polarization is 
given by
 
                                                                        (2) 
 
The intensities (I) in the parallel (II) and perpendicular ( ) direction compared to the 
excitation light are used for the calculation. Anisotropy is given by
 
                                                                                     (3) 
 
with I, II,  as stated above. MHCII peptide interactions can be described by common 
rate equations as follows
 
                   
 
 











Figure 6. Simplified schematic of an FP instrument. Excitation light passes through a 
wavelength cutoff filter and horizontal polarizer. The polarized light is directed to the 
sample by a dichroic mirror and the emitted light passed through the dichroic mirror to a 
beam splitter where it is split equally and directed to photomultiplier tubes after passing 







Figure 7. Schematic of the process of labeled peptide dissociating. As peptide dissociates the greater average rotation of the 
fluorophore in solution results in decreased polarization. The unlabeled competitor rapidly binds the peptide groove preventing 








Frequently, in protein interaction studies, polarization is the reported value. As 
Weber pointed out, the mathematics of the addition of polarizations when multiple 
species are present (in our case partially bound and partially unbound, contributing 
differentially to the overall polarization) is quite complicated (41). For this reason, 
anisotropy is the more accurate value and the value reported in the majority of our FP 
experiments. Finally, the anisotropy values were corrected for the variance in intensity 
seen when peptide is bound versus free in solution. The intensity of the fluorophore in 
bound peptide is somewhat less than free, due to the absorbance of emission and blocking 





Here, rI represents the anisotropic intensity, rf is the anisotropy of free peptide, If is 
intensity of free peptide and rb, Ib are the anisotropy and intensity, respectively, of peptide 












METHODS AND MATERIALS 
 
Protein Expression and Purification 
 
Expression and Purification of Recombinant  
Soluble HLA-DR1 Protein 
Soluble HLA-DR-1 was obtained from S2 insect cells transfected with 
recombinant HLA-DR1 lacking the cytoplasmic domains. Cells were stored at -80 C in a 
solution of Schneider‟s Drosophilia medium containing 10% heat inactivated fetal bovine 
serum (growth medium) with 10% dimethylsulfoxide. Prior to use cells were rapidly 
thawed at 37 C and suspended in 5 mL growth media. Cells were cultured at 26 C,  For 
3 days, the media was replaced daily by centrifugation at 100 x g for 5 minutes, decanting 
and replacing with fresh growth media. Cells were then allowed to grow to a density of 2 
to 6X 10^6 cells/mL before being subcultured at a seeding density of 5X10^5 cells/mL in 
complete growth media. When the desired volumes had been achieved cells were 
subcultured in 50% growth media and 50% serum free media to prepare for growth in 
serum free media. When a sufficient volume was achieved in this mixture to subculture 
the cells at a ratio of no greater than one part cell mixture to three parts serum free media 
the cells were subcultured in 100% serum free media in spinner flasks. Following 2 
hour‟s incubation, expression of soluble DR was induced by addition of 1 mM copper 





concentration of 100 µM in nanopure water and filter-sterilized over a 2 µm 
filter. Solid cells and debris were removed from the media by centrifugation at 3000 x g 
for 20 minutes. The supernatant was vacuum filtered over a sterile 2 µm filter and then 
sDR collected by immunoaffinity chromatography using a L243 antibody column. 
Protein was concentrated and buffer exchanged into pH 7.4 PBS by ultracentrifugation, 
using Amicon 30 kD cutoff filters. Protein concentration was determined by UV 
absorbance at 280 nm using an extinction coefficient of 56340 M-1 cm-1. Purity was 
confirmed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
(Figure. 8). 
Expression and Purification of Recombinant Soluble  
HLA-DM Protein 
Soluble HLA-DM, containing a FLAG protein, was obtained from S2 insect cells 
transfected with recombinant HLA-DM lacking the cytoplasmic domains. Cells were 
stored at -80 C in a solution of Schneider‟s Drosophilia medium containing 10% heat 
inactivated fetal bovine serum (growth medium) with 10% dimethylsulfoxide. Prior to 
use cells were rapidly thawed at 37 C and suspended in 5 mL growth media. Cells were 
cultured at 26 C. Daily, for 3 days, the media was replaced by centrifugation at 100 x g 
for 5 minutes, decanting and replacing with fresh growth media. Cells were then allowed 
to grow to a density of 2 to 6X 10^6 cells/mL before being subcultured at a seeding 
density of 5X10^5 cells/mL in complete growth media. When the desired volumes had 
been achieved cells were subcultured in 50% growth media and 50% serum free media to 
prepare for growth in serum free media. When a sufficient volume was achieved in this 




















mixture to three parts serum free media the cells were subcultured in 100% serum free 
media in spinner flasks. Following 2 hour‟s incubation, expression of soluble DM was 
induced by addition of 1 mM copper sulfate, activiating a metallothionein promoter. 
Stock copper sulfate was prepared at a 100 µM concentration in nanopure water and 
filter-sterilized over a 2 µm filter. Solid cells and debris were removed from the media by 
centrifugation at 3000 x g for 20 minutes. The supernatant was vacuum filtered over a 
sterile 2 µm filter and sDM collected by immunoaffinity chromatography using an anti-
FLAG antibody column. Protein was concentrated and buffer exchanged into pH 7.4 PBS 
by ultracentrifugation, using Amicon 30 kD cutoff filters. Protein concentration was 
quantified by UV absorbance at 280 nm using an extinction coefficient of 76000* M-1 
cm-1. Purity was confirmed by SDS-Page (Figure 9).  
Peptide Labeling 
Alexafluor 488 
Peptides were labeled with alexafluor 488 carboxylic acid, 2,3,5,6, 
tetrafluorophenyl ester (alexafluor488, Alexafluor488 TFP). Alexafluor 488 TFP 
specifically labels amine groups on proteins. Peptides were N-terminally acetylated and 
contained a single lysine for site specific labeling (Table 1). The final reaction solution 
contains approximately 2 moles peptide for each mole of Alexafluor488. Alexafluor488 
was dissolved in DMSO to a final concentration of 10 mg/mL, 0.57 M. To 50 L of the 
alexafluor solution, 140 L of 2 M peptide, 2.7 L triethylamine (TEA), and 6.3 L of 
DMSO were added. The reaction mixture was incubated at room temperature, protected 
from light, for 3 hours. The labeled peptide was separated by reverse phase 









































The mobile phase was 80% acetonitrile at a gradient from 10 to 90% over 15 minutes. 
The labeled fraction was collected manually and detected by an absorbance at 280 nm 
coincidental with a fluorescent peak resulting from an excitation of 490 nm and emission 
at 520 nm. The presence of peptide was determined by ultraviolet detection at 280 nm. 
Protein concentration was determined by the use of the extinction coefficient of the 
Alexafluor 488 dye of 71000, and the absorbance at its maximum wavelength of 495 nm. 
This calculation is an approximation, which is sufficient for this work as the peptide is 
not being used for quantitation until it has been loaded onto sDR at which point a more 
accurate determination of concentration is made. The labeled peptide was dried by 
centrifugal evaporation and reconstituted to a final concentration of approximately 2 mM 
in DMSO prior to use. The nomenclature used in the paper to refer to the alexaflour 488 
labeled peptides is the peptide name followed by superscripted 488, for example MAT488. 
Alexafluor350 
 
Peptides were labeled with Alexafluor350 succinimidyl ester (alexafluor350). 
Alexafluor350 specifically labels amine groups on proteins. Peptides were N-terminally 
acetylated and contained a single lysine for site specific labeling. The final reaction 
solution contains approximately 2 moles peptide for each mole of Alexafluor350. 
Alexafluor350 was dissolved in DMSO to a final concentration of 10 mg/mL, 0.57 M. 
To 50 L of the Alexafluor 350 solution, 140 L of 2 M peptide, 2.7 L triethylamine 
(TEA), and 6.3 L of DMSO were added. The reaction mixture was incubated at room 
temperature, protected from light, for 3 hours. A gradient of 0.085% trifluoroacetic acid 




peptide on a Rainin, Microsorb-MV, 5 m, 2.1X200, C18 column. The presence of 
labeled peptide was determined by increased absorbance at 280 nm coincidental with a 
fluorescent peak using excitation 350 nm and emission at 420 nm. Labeled fractions were 
collected manually and the approximate concentration determined as discussed in the 
previous section, using an extinction coefficient of 19000. The labeled peptide was dried 
by centrifugal evaporation and reconstituted in DMSO to a final concentration of 
approximately 2 mM prior to use. The nomenclature used in the paper to refer to the 





Peptides were labeled with 1-biotinamido-4-(4‟-[maleimidomethyl]cyclohexane-
carboxamido)utane (BMCC). Peptide had been previously biotinylated and stored at  
-20 C. Briefly the reaction procedure consisted of approximately 10 fold molar excess of 
BMCC in dimethylformamide (DMF). Reactions were performed at room temperature, 
for approximately 2 hours, followed by precipitation and acetone wash. Analysis was 
performed by reverse-phase HPLC. The nomenclature used in the paper to refer to the 
biotin labeled peptides is the peptide name followed by superscripted biot, for example 
MATbiot. 
 
MHCII Peptide Loading Reactions 
 
A 5 to 10-fold excess of the appropriately labeled peptide was incubated with 
sDR. Phosphate buffered saline (PBS) was added to 50 L of 100 M sDR and 25 L of 




37 C for one day. DR1-peptide (sDRp) complexes were separated from free peptide by 
size exclusion chromatography. The separation was performed with a Tosoh Biosep, 
QCPAK GFC200, 7.8 mm X 15 cm column, with an isocratic flow of pH 7.0 PBS. The 
presence of sDRp was confirmed by an increase in absorbance at 280 nm coincidental 
with a fluorescent peak indicative of the appropriate label. The sDRp fraction was 
collected manually. Purified sDRp was concentrated by ultracentrifugation with an 
Amicon Ultra 0.5 mL, 30 kD cutoff filter. sDRp concentration was determined using the 
following set of equations. To correct for the contribution of the dye to the absorbance at 
280 nm the equation 
 
                                                     Aprotein=A280-Amax *CF                                                  (7) 
was used.  
CF factor was determined by the following,  
 
                                      CF=A280 free dye/Amax free dye                                                                       (8) 
 
and the calculation of final protein was determined by the equation,  
 
                                          [sDRp]=Aprotein /                                        (9) 
using the extinction coefficient, , of the respective protein. Finally the degree of 
labeling  (DOL) was determined by the equation 
 
 




where dye indicates the extinction coefficient of the dye used (71000 for Alexafluor488 
and 19000 for Alexafluor 350).  
Peptide Dissociation Experiments 
Fluorescence Polarization 
 
Solutions of sDRp488 were prepared as described above. Reaction solutions were 
prepared in 10 mM citrate phosphate buffer, pH 5.0, with 150 mM NaCl and 0.05% 
tween-20. Depending on the experiment, the concentration of MHCII-peptide was varied, 
the concentration and sequence of the competitor peptide was varied or the concentration 
of HLA-DM was varied. Reactions were prepared in polypropylene tubes and heated for 
approximately 8 minutes at 37 C, after which 65 L of each reaction solution were 
transferred to wells of a 384 well, black, polystyrene plate and covered with 20 L of 
mineral oil to prevent evaporation. Polarization and anisotropy were determined using a 
Tecan, F200 plate reader, with an integrated heater to maintain a constant temperature of 
37 C. Wavelength cutoff filters were used to limit the excitation and emission 
wavelengths to 485 and 535 nm, respectively. The wavelength cutoff filters were nested 
in- line with polarizing lenses to enable polarization of the excitation and emission light. 
The instrument was set to deliver 25 flashes with a 20 sec integration time.  
Europium Dissociation Assay 
sDRpbiot was prepared as described above. Reaction solutions were prepared in 
0.1 M citrate-phosphate buffer, pH 5.0 with 0.2% NP40. To the citrate phosphate reaction 




various sequences. At predetermined time-points the reactions were stopped by adding 
150 L of a solution of 3:7 tris:MTBN.  The stopped reaction solutions were kept at  
4-8 C until all time-points had been collected. 96-well plates were coated with 100 L of 
2 g/mL L243, anti-HLA-DR1 antibody. The plates were incubated at 37 C for eight to 
24 hours to allow sufficient binding of the L243. The plates were blocked with MTB for 
30 minutes at room temperature, washed seven times with TTBS and 50 L of each 
reaction solution with 50 L of MTBN was added to the wells. The plates were incubated 
for 1.5 hours at 4 C and again washed with TTBS seven times. Two hundred µL of 0.1 
g/mL europium labeled streptavidin, diluted in assay buffer, was added to each well and 
incubated at 4 C for four to 24 hours. The plates were washed again with TTBS and 
developed with 100 L of enhancement solution A, for 10 minutes at room temperature 
with shaking, followed by 20 L of enhancement solution B for 10 minutes at room 
temperature, with shaking.  
Fluorescence readings were taken using a Perkin-Elmer, Victor3V, 1420 
multilabel counter. The excitation and emission wavelengths were set to 340 and 615 nm, 
respectively. Readings were taken over a 400 sec window, using a flash energy level of 
79. 
 
Peptide Dissociation by HPLC Size Exclusion Chromatography 
 
sDR was loaded with alexafluor350 or alexafluor488 labeled peptides as 
described above. Reactions were carried out in 10 mM citrate-phosphate buffer, pH 5.0 + 
150 mM NaCl and 0.05% tween-20. Depending on the experiment, the reaction solution 




competitors. The solutions were incubated at 37 C in a water bath. Addition of 150 L 
pH 8.8 tris terminated the reaction at specified time-points. A Shimadzu, series 10A 
HPLC was used to detect the free and bound peptide as soon as possible after termination 
of the reaction.  
Separation was performed with an isocratic flow of pH 7.0 PBS on a Tosoh 
Biosep size exclusion, QCPAK GFC200, 7.8mm X 15 cm column. Fluorescence readings 
were taken with the excitation and emission wavelengths set at 350 and 400 nm for 
alexafluor350 labeled peptides and 490 and 520 nm for alexafluor488 labeled peptides, 
respectively.  
Europium Competition Binding Assays 
 
To determine the affinity of a particular peptide for MHCII, competition-binding 
assays were performed. These assays used a platform similar to the europium assay 
described above to measure peptide dissociation. In these assays, a fixed concentration of 
1 M biotin labeled MAT and 100 M MHCII were incubated in 10 mM citrate 
phosphate buffer with 0.2% NP40, in the presence of varying concentrations of an 
unlabeled competitor. The solutions were incubated for 8 or more hours at 37 C and then 
the reactions stopped by adding 150 µL of 3:7 Tris:MTBN. The samples were added to a 
plate prepared as described above in the europium dissociation assay section. The plates 
were incubated for 1.5 hours at 4 C and washed with TTBS seven times. Two hundred 
L of 0.1 g/mL europium labeled streptavidin diluted in assay buffer were added to 
each well and incubated at 4 C for 4 to 24 hours. The plates were again washed with 




temperature followed by 20 L of enhancement solution B for 10 minutes at room 
temperature.  
Fluorescence readings were taken using a Perkin-Elmer, Victor3V, 1420 
multilabel counter. The excitation and emission wavelengths were set to 340 and 615 nm, 





Dissociation of Peptide in the Presence of Varying 
Concentrations of HLA-DM 
It has been shown that HLA-DM must be present for efficient peptide dissociation 
(Figure 10). Previous work had been done in our lab investigating the effect of varying 
concentrations of HLA-DM on peptide dissociation. For this study, we briefly revisited 
this topic to determine the concentration of HLA-DM necessary to attain accurate results 
with various peptides. Because the rate of dissociation varies with differing HLA-DM 
concentrations and differing MHCII-peptide complexes (Figure 11), we wanted to 
determine the concentration for which dissociation of higher affinity peptides would be 
rapid enough to achieve meaningful measurements. Most published methods use between 
1 M and 2 M HLA-DM, and this topic has been investigated thoroughly in our lab so it 
was only briefly revisited. Based on the findings of this and previous studies, we chose  
2 M HLA-DM for these experiments and unless otherwise noted that is the 
concentration used for the following experiments.  
 
Determination of the Lowest Effective sDRp Concentration 
 
To begin the MHCII dissociation experiments we wanted to determine the lowest  
sDRp concentration at which dissociation could be reliably determined. By decreasing 







Figure 10. Dissociation of MAT488 in the presence and absence of HLA-DM. In general, in the absence of HLA-DM a 



















accurate measure of dissociation could be made in the absence of competitor. To 
determine the lowest concentration at which dissociation assays could be performed, 
sDRMAT
488 solutions were prepared at decreasing concentrations and dissociation 
analyzed. Dissociation was followed over a period of approximately 5 hours and the 
dissociation rate was determined. The criteria for acceptability were that the dissociation 
rate differed no more than 20% from the rate calculated with 50 nM complex in the 
presence of competitor, as is used in a typical dissociation assay, while still achieving 
acceptable data fits (R2 0.98 or greater). While all of the concentrations tested met the 
first criteria, the concentrations below 5.9 nM began to deteriorate in regard to curve fit 
(Table 2 and Figure 12).  
Dissociation of Peptide in the Presence of 
Various Affinity Competitors 
In the absence of a “push off” mechanism the affinity of the competitor peptide 
(assuming the peptide is able to bind MHCII) should only minimally alter the rate of 
dissociation of a pre-bound peptide. To determine the affect of competitor affinity, we 
investigated the dissociation of labeled peptides from MHCII in solution with competitor 
peptides of varying affinities. Three well-characterized peptides were used to determine 
the affect of high, intermediate, and low affinity competitors. An additional, extremely 
low affinity peptide, designed in our lab, was also included in select experiments. HA, 
MAT, CLIP, and OPT3 were chosen to represent the range of affinit ies (Table 1). HA is a 
high affinity peptide, derived from the hemagglutinin portion of influenza virus; MAT,  
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Competitor 5.9nM 2.9 nM 1.5 nM 0.75 nM 
Span 1.031 1.218 1.22 1.623 1.725 
K 0.000003529 0.000004618 0.000004589 0.000006178 0.000007322 
Plateau 0.4988 0.5601 0.6081 0.7221 0.6861 














the intermediate affinity peptide, comes from the matrix envelope of influenza; and CLIP, 
which has been discussed at length previously, was chosen to represent the low affinity 
range. OPT3 had key anchor residues modified, resulting in a peptide for which 
appreciable interactions with MHCII were undetectable. When we attempted to load 
MHCII with OPT3 in our loading procedure, no binding was detected. In a competition-
binding assay, no competitive effect was seen even at 200 µM, 20 times the typical 
concentration of competitor in our dissociation assay (Figure 13).  
The dissociation of MAT488 from sDR at 107 nM, 50 nM, 21 nM, and 5.9 nM was 
analyzed in the presence of various competitors (Figure 14). At each concentration, HA, 
MAT, and CLIP effected dissociation at approximately the same rate; in the absence of 
competitor or when OPT3 is used as competitor, the apparent rates are significantly 
decreased at the higher concentrations (Table 3). One can notice in Figure 14 that the 
dissociation never fully reaches a plateau. The Alexafluor dye series has been shown to 
be highly stable and resistant to the photobleaching effect seen with some other dyes. We 
verified that over the course of the assay the label was not losing intensity due to a 
photobleaching or other effect of which we are unaware (Figure 15). Based on the 
stability of the dye we hypothesized that the continual, slow dissociation seen is the result 
of a process other than regular peptide dissociation. In this process the sDR is being 
slowly converted to a non-binding form.  
 Similar experiments were performed by HPLC and Europium assay, with other 
sDRp complexes to verify that the rate of dissociation was not affected by the 
measurement technique or the peptide used. The dissociation of CLIP350 (Figure 16) and 





Figure 13. Competition binding assay comparing the affinity of OPT3 to the other peptides used in these assays. Note that OPT3 



























Competitor CLIP HA MAT OPT3 
107 nM 1.82E-04 9.48E-05 1.08E-04 9.66E-05 1.89E-04 
50 nM 1.74E-04 1.25E-04 1.39E-04 1.16E-04 1.85E-04 
21 nM 1.41E-04 1.27E-04 1.47E-04 1.22E-04   




Figure 15. Labeled peptide control. Steady signal is seen for the duration of the experiment (150000 minutes). The X axis was 



























Figure 18. Dissociation of HAbiot during a 36 hour incubation. X axis labels indicate the competitor used in the reaction. Fraction 








were determined by europium assay. In all cases, the dissociation is minimally affected 
by the sequence of the competitor peptide. These data clearly support our theory of a 
model of peptide binding based on mass action.  
 
Dissociation at Various Concentrations of Complex in  
the Absence and Presence of Competitor 
To look more specifically at how rebinding affects the apparent rate of 
dissociation we devised a series of experiments in which the labeled peptide loaded on 
the sDR and the unlabeled competitor were the same. In this series of experiments the 
concentration of sDRp was sequentially decreased and one reaction set had 10 M added 
competitor while the other set lacked competitor. Each of the samples contained 2 µM 
HLA-DM. The final concentration of complex used in these experiments ranged from 
100 nM to 6.25 nM. As we showed previously reliable measurements could be achieved 
to a concentration of 5.9 nM.  
By significantly diluting the concentration of sDRp, we wanted to minimize the 
affect of rebinding. As the complex becomes increasingly more dilute, the dissociating 
peptide is less likely to rebind due to Brownian motion. In the absence of a push off 
mechanism, at low enough concentrations, we expect the rate of dissociation in the 
absence of competitor to be equal to the rate in the presence of competitor. As Figure 19 
shows, the rate of dissociation in the presence of competitor shows no significant 
variance, regardless of the concentration of complex. However, as can be seen in this 
figure, in the absence of competitor as the concentration sDRp decreases the plateau also 





Figure 19. Dissociation of DRMAT  at various concentrations with and without competitor. In the absence of competitor the plateau 
trends downward as the concentration of complex is decreased. At the lowest concentration the plateau is near equivalent with the 
plateaus of the samples with competitor in solution. Note that even in the presence of competitor it appears that an equilibrium is 








Although the results from the previous section, that the affinity of the competitor 
does not significantly alter the rate of dissociation led us to further question the validity 
of a two-peptide mechanism, these results clearly implicate peptide rebinding in the 
alteration of rates seen in the absence of competitor. The results presented in this section 
are paramount to supporting our theory that peptide dissociation from MHCII is 
dependent on the affinity of the bound peptide and unaffected by the presence of other 
peptides. Figure 19 shows that as the sDRp concentration decreases, in the absence of 
competitor, the apparent rate of dissociation approaches the rate seen in the presence of 
competitor. These data indicate that the apparent shift in rates seen when competitor is 
present are merely a result of a shift in the equilibrium due to the ability of dissociated 
peptide to rebind at higher concentrations in the absence of a molecule to block the open 
binding site. Similar experiments were conducted with VV18R (Figure 20) and OPT2 
(Figure 21). 
Dissociation Rates at Various Competitor Concentrations 
      Our data to this point have been focused on the presence or absence of competitor 
and how the affinity of the competitor effects dissociation. We next wanted to determine 
the outcome if the sDRp was held at a steady concentration and the competitor peptide 
concentration was varied. These results are more difficult to interpret. Our theory that 
dissociation is a random process based on affinity, predicts that as the concentration of 
competitor increases that the competitive action to inhibit rebinding would reach a 
maximum after which no additional difference in dissociation would be seen. A push off 
mechanism, however, might produce a different result. Based on the two peptide model, 





















increase at even higher concentrations due to the ability of the competitor to due to the 
ability of the competitor to more effectively „push off‟ the bound peptide. Competitor 
was tested from 0 to 10 M. The data presented in Figures 22 and 23 are less than ideal. 
Ideally the competitor concentration tested would have included much higher 
concentrations to show that either the dissociation rate continues to increase as 
competitor increases or it reaches a maximum at a certain level of competitor and further 
increases do not affect the dissociation rate after this point. Because of the difficulty in 
interpreting these data I discontinued these experiments to conserve reagents for more 
crucial experiments. I felt that regardless of the outcome, the results might be interpreted 
as supporting either hypothesis.  
Additional Experiments/Method Development 
In addition to the major experiments presented in this body of work, some 
additional method development projects were conducted which deserve mention, 
although they were not fully completed. An antibody based plate assay was briefly 
worked on which was designed to immobilize a biotin labeled peptide, while allowing 
sDR to be free in solution following dissociation. The effect of varying concentrations of 
competitor on a fixed concentration of sDRp was also analyzed.  
The europium immunofluorescence assay was designed as follows. Plates were 
coated with streptavidin. sDRpbiotin was added to the solution in MTB and allowed to 
incubate for a specific period of time, after which the reaction would be stopped by 
adding a solution of 3:7, MTBN:Tris. After completion of the timepoints the plates were 





Figure 22. Dissociation of MAT488 from sDR at a concentration of 21 nM and in the presence of varying concentrations of 












Figure 23. Dissociation of MAT488 at a concentration of 108 nM from sDR in the presence of varying concentrations of 






be bound to immobilized peptide, would be detected by addition of an anti-DR antibody 
followed by europium labeled mouse anti-IgG. Figure 24 shows a schematic of the 
procedure. During the initial method development, I attempted to determine the useful 
concentration of streptavidin and sDRpbiot , by using a more simplified version in which 
streptavidin was coated on the plate and biotinylated antibody was incubated followed by 
direct detection with europium labeled anti-IgG. During these initial experiments the 
results were highly variable, leading to difficulty in determining the exact concentrations 
required.  
Ideally this assay would provide a sensitive measure of peptide dissociation in 
which only one of the elements was able to freely move about in solution. The 
immobilization of one of the elements would minimize the ability to rebind due to 
Brownian motion, and possibly higher sensitivity would enable detection at even lower 
concentrations than with the FP assay, and lead to a further minimization of rebinding 
than was achievable with FP. With additional method development it appears that this 
assay is feasible. I worked on the variability seen by attempting to make fresh reagents 
but this did not seem to do much to decrease the variability. Some of the possible 
problems that might be encountered with this assay are the physical constraints of the 
sDRp binding closely to the plate, or in an inverted position. Additionally, a technique in 
which the stopped time-points could be removed from the plate, such as removable well 
plates, so that the stopped point could be refrigerated while the remainder of the time-















Here we have presented data to support our theory that peptide dissociation occurs 
independent of other peptides in solution, and the rate at which it occurs is based on the 
affinity of the bound peptide. If a „two-peptide‟ or „push off‟ mechanism did exist then 
one would expect that dissociation rates would be significantly affected based on the 
affinity of the competitor peptide. This is not what we see, as presented in the section 
describing peptide dissociation in the presence of various peptides. What is seen is that 
for any peptide which is able to bind MHCII, the rate of dissociation is nearly identical 
regardless of the peptide. The minor variances seen are likely a result of the process of 
MHCII degradation over time. In the absence of peptide MHCII undergoes an 
irreversible alteration in its configuration resulting in an inability to bind peptide. This is 
evident when viewing the FP dissociation graphs, as there is a continual but very slow 
lowering of the plateau over time. Were sDR and peptide to reach a true equilibrium, at 
which dissociation and binding were equivalent, the plateau would be flat. Initially I 
thought that the gradual loss over time might be due to a photobleaching type effect, but 
tested this theory using p488 in solution. For these samples, following an initial 
equilibration period, the polarization and intensity was displayed as a flat line for the 
duration of the experiments.  
 In the case where the competitor was an extremely low affinity peptide (OPT3), 
we showed that having that peptide in solution even at excess was equivalent to having
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 no competitor at all. We followed up these experiments with a series of experiments in 
which the dissociation of peptide from sDR at increasingly low concentrations of  
complex was determined. In these experiments we show that at lower concentrations of 
complex, the apparent rate of dissociation approaches the rate seen in the presence of 
competitor. The peptide used in the complex was also used as competito r, to eliminate the 
competitor affinity as a variable. The point at which the plateau is reached can be thought 
of in two ways. The first is that the plateau is the point at which rebinding of the labeled 
peptide is equivalent to dissociation. In this case, although peptide continues to 
dissociate, the overall effect determined instrumentally is that there is no net dissociation. 
The other way that the plateau can be viewed is the point at which peptide can no longer 
dissociate. This is how proponents of the „push-off‟ mechanism view it. By decreasing 
the sDRp concentration we showed that the plateau is most likely a representation of the 
first view, in which rebinding and dissociation are occurring at the same rate. These 
findings clearly implicate peptide rebinding in the difference of rate seen in the absence 
and presence of competitor.  
 Overall the data presented produce a compelling argument against a „push-off‟ 
mechanism. This is the first, that we can determine, study to be done that was solely 
intended to determine the effect of the competitor peptide in peptide MHCII dissociation 
experiments. Although the assumption has traditionally been made that the competitor 
was only blocking the binding site upon peptide dissociation, it is important to verify that 
this is the case. We also assume that biologically the process of peptide dissociation 
occurs in a similar fashion, independent of other peptides in solution. Ferrante et. al. 




MHCII peptide dissociation. It was an interesting argument but one in which a key 
parameter was left untested and that was the ability of peptide to rebind following 
dissociation. They stated the assumption in the paper that at the low concentrations at 
which these experiments were done it was unlikely that peptide would ever reach a point 
in solution at which it could effectively rebind by Brownian motion. We fully tested and 
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